Lymphoma Canada is preparing a submission to the panCanadian Oncology Drug Review (pCODR) for:
Idelalisib (Zydelig) for the treatment of patients with follicular lymphoma who have received at least two prior systemic regimens and are refractory to both rituximab and an alkylating agent.
You can help by completing our survey, which will provide us with the patient and caregiver input required for the submission. pCODR uses this information to help them make recommendations to the provinces and territories regarding funding for new cancer drugs.
You do not need to live in Canada to complete this survey.
BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS NEW TREATMENT IN CANADA.
The survey will be open until midnight Pacific Time on Friday, April 1st and should take 10 minutes of your time.